Media Contact:
Stephen Majors
Vice President, Global Communications
smajors@alliancerm.org
Carlsbad, CA
New analysis shows that durable cell and gene therapies have clinical success rates between two and three times higher than other types of treatments.
Carlsbad, CA
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines, today announced the election of its 2024 Board of Directors.
Washington, DC
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the engineered cell therapy and genetic medicines sector, announced the promotion of Michael Lehmicke to Senior Vice President, Science & Industry Affairs, effective immediately.
BRUSSELS
Without changes recognizing the unique characteristics of ATMPs, the EU’s new Joint Clinical Assessment will fail to deliver the next generation of transformative therapies to rare disease patients, according to the Alliance for Regenerative Medicine, EveryLife Foundation for Rare Diseases, and Rare Diseases International.
